| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
| Company Name: |
cjbscvictory |
| Tel: |
13348960310 13348960310 |
| Email: |
3003867561@qq.com |
CDD0102 manufacturers
- CDD0102
-
- $1980.00
-
2026-04-21
- CAS:146422-58-4
- Purity:
- Supply Ability: 10g
- CDD0102
-
- $1980.00
-
2025-08-22
- CAS:146422-58-4
- Purity:
- Supply Ability: 10g
|
| | CDD0102 Basic information |
| Product Name: | CDD0102 | | Synonyms: | CDD0102;CDD0102A;Pyrimidine, 5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydro-;CDD0102,CDD-0102 | | CAS: | 146422-58-4 | | MF: | C8H12N4O | | MW: | 180.21 | | EINECS: | | | Product Categories: | | | Mol File: | 146422-58-4.mol |  |
| | CDD0102 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO |
| | CDD0102 Usage And Synthesis |
| Uses | CDD0102 is a potent M1 Muscarinic receptor agonist. | | in vivo | After i.p. injections, CDD0102 (CDD-0102) crosses the blood-brain barrier (BBB) in a dose-dependent manner. In toxicological studies, the LD50 of CDD0102 is 190 mg/kg following i.p. injections and greater than 1,000 mg/kg following oral administration. In follow-up studies, after oral administration at a dose of 10 mg/kg, CDD0102 fully reverses memory deficits associated with IgG-192 saporin administration. Again, no side effects are observed at this dose[1]. | | References | [1] Messer WS Jr. The utility of muscarinic agonists in the treatment of Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):187-93. DOI:10.1007/s12031-002-0031-5 |
| | CDD0102 Preparation Products And Raw materials |
|